Panbela Therapeutics, Inc. (NASDAQ:PBLA – Get Free Report) shares rose 2.3% during mid-day trading on Monday . The company traded as high as $0.38 and last traded at $0.36. Approximately 14,501 shares were traded during trading, a decline of 96% from the average daily volume of 359,221 shares. The stock had previously closed at $0.35.
Analyst Ratings Changes
Several research firms recently commented on PBLA. HC Wainwright reaffirmed a “neutral” rating on shares of Panbela Therapeutics in a research note on Monday, June 24th. Roth Mkm restated a “buy” rating on shares of Panbela Therapeutics in a report on Wednesday, March 27th.
Check Out Our Latest Stock Analysis on PBLA
Panbela Therapeutics Stock Down 2.8 %
Panbela Therapeutics (NASDAQ:PBLA – Get Free Report) last posted its earnings results on Wednesday, May 15th. The company reported ($2.28) EPS for the quarter, missing the consensus estimate of ($1.23) by ($1.05). As a group, equities analysts anticipate that Panbela Therapeutics, Inc. will post -8.38 EPS for the current fiscal year.
About Panbela Therapeutics
Panbela Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company's lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial.
Further Reading
- Five stocks we like better than Panbela Therapeutics
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- Real Estate Stock Signals a Boom in Manufacturing Activity
- Retail Stocks Investing, Explained
- This Medical Giant’s Stock Rebounds: A 15% Upside Is the Minimum
- Overbought Stocks Explained: Should You Trade Them?
- Financial Giant’s Shares Soar on EPS Beat and Record Asset Levels
Receive News & Ratings for Panbela Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Panbela Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.